Since the discovery of tumor-specific antigens is not always a feasible task, researchers have suggested targeting the tumor-specific glycoforms (called T, Tn, or sialyl Tn glycoforms) of commonly known TAAs (such as MUC1) (51). This evidence concerns the gene MUC1 and neoplasm.